A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

Pfizer logo

Pfizer

Status and phase

Completed
Phase 1

Conditions

Asthma

Treatments

Drug: PF-03526299
Drug: Fluticasone propionate
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00877539
A9291002

Details and patient eligibility

About

PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Enrollment

29 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females 18-60 years
  • Mild asthma
  • Atopic to allergens

Exclusion criteria

  • Unstable asthma
  • Smokers or recent ex-smokers
  • Recent allergen challenge

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

29 participants in 3 patient groups, including a placebo group

PF-03526299
Experimental group
Treatment:
Drug: PF-03526299
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
Fluticasone propionate
Active Comparator group
Treatment:
Drug: Fluticasone propionate

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems